期刊
HYPERTENSION
卷 37, 期 2, 页码 250-254出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.HYP.37.2.250
关键词
obesity; beta-blockers; body weight; hypertension, obesity
One of the arguments put forward against the primary use of P-blockers has been concern about adverse metabolic effects, such as unfavorable effects on lipids or insulin sensitivity. Another less-appreciated potential drawback is their propensity to cause weight gain in some patients, In 8 evaluable prospective randomized controlled trials that lasted greater than or equal to6 months, body weight was higher in the beta -blocker than in the control group at the end of the study. The median difference in body weight was 1.2 kg (range -0.4 to 3.5 kg), A regression analysis suggested that beta -blockers were associated with an initial weight gain during the first few months. Thereafter, no further weight gain compared with controls was apparent. There was no relationship between demographic characteristics and changes in body weight. Based on these observations, the first-line use of beta -blockers in obese hypertensive patients should be reviewed. Obesity management in overweight hypertensive patients may be more difficult in the face of beta -blocker treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据